Foundation Fighting Blindness
J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
2025-05-15
Despite missing the primary endpoint, the treatment improved vision for some patients.
Comments (3)
More Episodes
All Episodes>>
Get this podcast on your phone, Free
Create Your Podcast In Minutes
- Full-featured podcast site
- Unlimited storage and bandwidth
- Comprehensive podcast stats
- Distribute to Apple Podcasts, Spotify, and more
- Make money with your podcast
It is Free
